BCYC
Bicycle Therapeutics LtdNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$282.74M
P/E Ratio
—
EPS
$-3.15
Beta
1.54
52W High
$9.18
52W Low
$3.97
50-Day MA
$4.69
200-Day MA
$6.16
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Bicycle Therapeutics Ltd
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments. The company is headquartered in Cambridge, the United Kingdom.
Fundamentals
| Revenue (TTM) | $63.50M |
| Gross Profit (TTM) | $-155.27M |
| EBITDA | $-232.23M |
| Operating Margin | -7382.00% |
| Return on Equity | -33.80% |
| Return on Assets | -19.40% |
| Revenue/Share (TTM) | $0.92 |
| Book Value | $7.95 |
| Price-to-Book | 0.52 |
| Price-to-Sales (TTM) | 4.45 |
| EV/Revenue | 21.22 |
| EV/EBITDA | -2.14 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -91.10% |
| Shares Outstanding | $50.37M |
| Float | $1.88M |
| % Insiders | 4.49% |
| % Institutions | 73.65% |
Historical Volatility
HV 10-Day
38.01%
HV 20-Day
37.05%
HV 30-Day
39.53%
HV 60-Day
45.37%
HV Rank
10.7%
Volatility is currently contracting
Analyst Ratings
Consensus ($12.62 target)
2
Strong Buy5
Buy4
HoldMore HEALTHCARE Stocks
Data last updated: 6/13/2026